We’ve found a hidden “switch” for Alzheimer’s, and the best part is that we have promising candidates to turn it off

Researchers identified cPLA2 as a key driver of APOE4-linked brain inflammation in Alzheimer’s disease.

They are using computer screening to find inhibitors that can cross the blood-brain barrier and block the enzyme.

Several candidate molecules have already reduced neuroinflammation in preclinical models.

The approach could support more precise, personalized Alzheimer’s treatments instead of one-size-fits-all drugs.